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Abstract
Background: Acetaminophen, the major active metabolite of acetanilide in man, has become one of the most popular over-
the-counter analgesic and antipyretic agents, consumed by millions of people daily. However, its mechanism of action is still
a matter of debate. We have previously shown that acetaminophen is further metabolized to N-(4-hydroxyphenyl)-
5Z,8Z,11Z,14Z -eicosatetraenamide (AM404) by fatty acid amide hydrolase (FAAH) in the rat and mouse brain and that this
metabolite is a potent activator of transient receptor potential vanilloid 1 (TRPV1) in vitro. Pharmacological activation of
TRPV1 in the midbrain periaqueductal gray elicits antinociception in rats. It is therefore possible that activation of TRPV1 in
the brain contributes to the analgesic effect of acetaminophen.
Methodology/Principal Findings: Here we show that the antinociceptive effect of acetaminophen at an oral dose lacking
hypolocomotor activity is absent in FAAH and TRPV1 knockout mice in the formalin, tail immersion and von Frey tests. This
dose of acetaminophen did not affect the global brain contents of prostaglandin E2 (PGE2) and endocannabinoids.
Intracerebroventricular injection of AM404 produced a TRPV1-mediated antinociceptive effect in the mouse formalin test.
Pharmacological inhibition of TRPV1 in the brain by intracerebroventricular capsazepine injection abolished the
antinociceptive effect of oral acetaminophen in the same test.
Conclusions: This study shows that TRPV1 in brain is involved in the antinociceptive action of acetaminophen and provides
a strategy for developing central nervous system active oral analgesics based on the coexpression of FAAH and TRPV1 in the
brain.
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Introduction
In 1948, Brodie and Axelrod demonstrated that acetaminophen
is the major active metabolite of acetanilide in man [1]. Since
then, acetaminophen has become one of the most popular over-
the-counter analgesic and antipyretic agents, consumed by
millions of people daily. Although acetaminophen shares some
pharmacological properties with the cyclooxygenase (COX)
inhibitors, its anti-inflammatory effect is weak and it is devoid of
the typical adverse effects of the COX inhibitors, indicating partly
different mechanisms of action. The additive analgesic effects of
acetaminophen and COX inhibitors, as observed in several
clinical trials [2], may also reflect non-overlapping mechanisms
of action. Furthermore, acetaminophen is active in human and
animal models of acute non-inflammatory pain, which are
considered insensitive to COX inhibitors [3–11].
Acetaminophen is a high dose analgesic and antipyretic agent,
undergoing extensive metabolism in the body. We have recently
shown that acetaminophen is metabolized by FAAH to the N-
acylphenolamine AM404 in the rodent nervous system and that
inhibitors of FAAH prevent the antinociceptive effect of
acetaminophen in rat [6,12]. This compound, which possesses
analgesic activity in models of nociceptive and neuropathic pain
[13–20], was originally proposed to be an inhibitor of cellular
uptake and degradation of anandamide [21]. However, subse-
quent studies have shown that AM404 is also a potent activator of
the capsaicin receptor TRPV1 and an inhibitor of COX in vitro
[12,22,23]. Interestingly, some of its antinociceptive effects were
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downstream target(s) for the antinociceptive effect of acetamino-
phen is an open question.
This study explores the role of TRPV1 in the antinociceptive
effect of acetaminophen in rodent models of chemical (formalin
test), thermal (tail immersion test) and mechanical (von Frey test)
pain. These nociceptive tests are intact in TRPV1
2/2 mice and
sensitive to acetaminophen, but considered to be partially or
completely insensitive to COX inhibitors [3,6,8,9,24,25]. The
levels of prostanoids and endocannabinoids in brain were also
measured to address the possibility that acetaminophen or its
metabolites interferes with COX or the elimination of endocan-
nabinoids in this organ. We found that acetaminophen at a dose
that did not affect spontaneous locomotor activity or the contents
of PGE2 and endocannabinoids in brain produced a robust
antinociceptive effect that was absent in TRPV1
2/2 mice and
abolished by systemic or intracerebroventricular injection of
capsazepine.
Results
An initial set of experiments was designed to establish a dose
and a route of administration (oral versus parenteral) of
acetaminophen that produced robust responses in nociceptive
tests without impairing motor activity. These experiments showed
that an oral dose of 200 mg/kg in mice produced robust
antinociceptive effects in the formalin, the tail immersion and
the von Frey tests, but did not affect the spontaneous locomotor
activity (Fig. 1, left panel). Such a clear separation of antinoci-
ceptive and hypolocomotor effects was not observed when
acetaminophen was administered intraperitoneally (Fig. 1, right
panel). Based on these studies, we selected an oral dose of 200 mg/
kg in the subsequent nociceptive tests in mice. As shown
previously, oral doses up to 300 mg/kg do not reduce the
spontaneous locomotor activity in the rat [6].
Fatty acid amide hydrolase is a key enzyme in the metabolism of
acetaminophen to potentially analgesic N-acylphenolamines,
including AM404 [12]. We therefore examined the antinocicep-
tive effect of acetaminophen in FAAH
2/2 mice and wild-type
littermates in the various tests. In FAAH
+/+ mice, acetaminophen
reduced the time spent biting and licking during the first and the
second phases of the formalin test and increased the withdrawal
thresholds in the tail immersion and the von Frey tests (Fig. 2 A, B
and C). However, acetaminophen failed to produce antinocicep-
tion in the same tests in FAAH
2/2 mice (Fig. 2 A, B and C). The
endocannabinoids anandamide and 2-arachidonoylglycerol are
effectively metabolized by FAAH and monoacylglycerol lipase,
respectively, and thus we considered the possibility that acetamin-
ophen increases the brain levels of analgesic endocannabinoids by
inhibition of their metabolism. However, neither oral nor
intraperitoneal administration of acetaminophen affected the
global content of the endocannabinoids in the mouse or rat brain
(Table S1, Fig. S1). Collectively, our results show that the
antinociceptive action of acetaminophen is dependent on FAAH,
but not mediated by changes in the levels of endocannabinoids in
brain.
Substantial levels of AM404 were detected in brain after
systemic administration of acetaminophen and p-aminophenol in
rodents [12]. This together with our previous finding that AM404
inhibits COX in vitro [12] prompted us to measure the content
of PGE2 in mouse brain after oral administration of acetamino-
phen at a dose of 200 mg/kg. However, no difference in the
PGE2 contents was observed between acetaminophen-treated
(3.061.1 nmol/mg protein) and vehicle-treated (3.461.3 nmol/
mg protein) animals (n=9). We next compared the effects of
acetaminophen and the competitive COX inhibitor ibuprofen in
the various nociceptive tests in mice and rat (Fig. 3). Ibuprofen was
administered intraperitoneally at a dose of 100 mg/kg that
produced more than 90% inhibition of the PGE2 content in the
mouse brain (Fig. S2 A). In both mice and rats, acetaminophen
and ibuprofen reduced the nocifensive behavior during the second
phase of the formalin test (Fig. 3 A and B). However, only
acetaminophen inhibited the first phase of the formalin test (Fig. 3
A and B). In the tail immersion and the von Frey tests in mice,
acetaminophen, but not ibuprofen, increased the withdrawal
thresholds (Fig. 3 C and D). The different pharmacological profiles
of acetaminophen and ibuprofen in the biochemical and
behavioral assays indicate that acetaminophen has antinociceptive
effects that cannot be attributed to inhibition of COX.
To understand the potential role of AM404 in the pharmaco-
logical action of acetaminophen, we first examined the effect of
intracerebroventricular injection of AM404 at different doses in
the mouse formalin test. AM404 at a dose of 10 nmol/mouse
inhibited the first phase of the formalin test when injected 5 min
prior to formalin (Fig. 4 A). The second phase of the formalin test
was not affected by this dose of AM404, possibly due to a rapid
elimination of AM404 in the brain in the absence of its precursor
p-aminophenol [12,26]. However, a significant effect was observed
on this phase when AM404 was injected 10 min after formalin
(Fig. 4 A). Additional experiments showed that the effect of
AM404 on the first phase of the formalin test was absent when
AM404 was co-administered with the TRPV1 blocker capsazepine
(100 nmol/mouse) as well as in TRPV1
2/2 mice (Fig. 4 B). In
contrast, intraplantar injection of AM404 at a dose of 10 nmol/
mouse or higher produced an acute nocifensive response. This
pronociceptive effect was absent in TRPV1
2/2 mice (Fig. 4 C).
Taken together, these experiments show that AM404 via
activation of TRPV1 produces antinociception when injected into
the brain, but pronociception when injected into the paw.
We next studied the involvement of TRPV1 in the antinoci-
ceptive effect of acetaminophen in mice and rats. While
acetaminophen inhibited both phases of the formalin test and
increased the withdrawal thresholds in the tail immersion and the
von Frey tests in TRPV1
+/+ mice, it did not produce antinocicep-
tion in TRPV1
2/2 mice (Fig. 5 A, B and C). In rats,
administration of acetaminophen at an oral dose of 300 mg/kg
reduced both phases of the formalin test (Fig. 5 D). Pretreatment
with capsazepine (10 mg/kg i.p.) prevented this antinociceptive
effect of acetaminophen (Fig. 5 D). To address whether TRPV1 in
brain is involved in the antinociceptive effect of acetaminophen,
we injected capsazepine intracerebroventricularly 5 min before
administration of acetaminophen at an oral dose of 200 mg/kg in
the mouse formalin test. This treatment prevented the effect of
acetaminophen on both the first and second phases of the formalin
test (Fig. 5 E). These experiments demonstrate that the
antinociceptive effect of acetaminophen is dependent on TRPV1
and indicate that TRPV1 in brain mediates this effect.
As shown previously in mice, acetaminophen injected subcuta-
neously at doses of 200 mg/kg and above reduces the PGE2
content in the brain and produces antinociception in the writhing
test [7]. Using tandem mass spectrometry, we found that
acetaminophen given intraperitoneally at a dose of 300 mg/kg
reduced the content of prostanoids in the brain (PGE2), kidneys
(PGE2) and blood (thromboxane B2), thus displaying a pharma-
cological profile similar to that of the COX inhibitor ibuprofen
(Fig. S2 A). Furthermore, acetaminophen at this dose inhibited
each phase of the formalin test to the same extent in TRPV1
2/2
mice and their wild-type littermates (Fig. S2 B). Thus, a reduction
Brain TRPV1 and Acetaminophen
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to the TRPV1-independent effect of high doses of acetaminophen
on the second phase of the formalin test. Although the mechanisms
behind these effects remain to be determined, our study clearly
shows that the antinociceptive effect of acetaminophen at an oral
dose of 200 mg/kg is independent of COX, but dependent on
both FAAH and TRPV1.
Discussion
We have previously described a new role for FAAH in the
metabolism of acetaminophen, leading to the formation of N-
acylphenolamines, such as AM404, in the brain [12]. As shown in
vitro, AM404 interferes with several important targets and
mechanisms in the pain pathways, including TRPV1, COX and
Figure 2. The antinociceptive effect of acetaminophen is dependent on FAAH. The effect of acetaminophen (AcAP; 200 mg/kg p.o.) was
assessed in (A) the formalin test (B) the tail immersion test and (C) the von Frey test. In FAAH
2/2 mice, acetaminophen failed to produce
antinociception, while it was effective in FAAH
+/+ mice in the same tests. All tests were performed 20 min after acetaminophen administration. In the
tail immersion and von Frey test tests, results are expressed as MPE (%): [(post-treatment score – pre-treatment score)/(cut-off value – pre-treatment
score)6100]. Basal pre-treatment threshold responses were 7.7360.32 and 8.0560.29 s in the tail immersion test and 0.5560.03 and 0.6260.06 g in
the von Frey test for FAAH
+/+ and FAAH
2/2 mice, respectively. Data are presented as mean 6 SEM (n=6–8 per group). *P,0.05, **P,0.01 compared
to vehicle.
doi:10.1371/journal.pone.0012748.g002
Figure 1. Dose-effect relationship of acetaminophen on locomotor activity and nociception in mice. Left and right panels of the figure
show the effects of acetaminophen after oral (p.o.) and intraperitoneal (i.p.) administration, respectively. (A) Animals were placed in actimetry boxes
(Actisystem, Apelex) and their movements were assessed by determining the number of crossings of light beams during 15 min. Intraperitoneal
doses induced a higher reduction in spontaneous activity than oral doses. The test was performed 20 min after acetaminophen administration. Data
are given as mean 6 SEM (n=6). *P,0.05, **P,0.01 compared to vehicle. (B–D) Mice were submitted to chemical (B), thermal (heat; C) and
mechanical (D) stimuli before and 20 min after oral or intraperitoneal administration of acetaminophen at the highest dose that was without effect
on locomotor activity (200 mg/kg p.o. and 100 mg/kg i.p.). Data are given as mean 6 SEM (n=6). *P,0.05, **P,0.01 compared to vehicle (A, B) or
before treatment (C, D).
doi:10.1371/journal.pone.0012748.g001
Brain TRPV1 and Acetaminophen
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12748the cellular uptake and degradation of endocannabinoids.
However, the relevance of this novel metabolic pathway and its
downstream target(s) for the antinociceptive effect of acetamino-
phen remained an open question.
In the present study, we provide evidence that TRPV1 mediates
the antinociceptive effect of acetaminophen in the formalin test in
the mouse and rat as well as the tail immersion and the von Frey
tests in the mouse. Furthermore, the lack of antinociception in
FAAH
2/2 mice underscores the critical role of FAAH and the
potential involvement of N-acylphenolamines, such as AM404, in
the antinociceptive effect of acetaminophen in rodents [6,12]. This
action of acetaminophen is independent of COX, because
acetaminophen did not affect the level of prostaglandins in the
brain at the dose used, and ibuprofen could not mimic the
antinociceptive effect of acetaminophen in the various tests of non-
inflammatory pain, although it substantially reduced the content of
PGE2 in the brain and peripheral tissues.
Our previous observation that AM404 is produced mainly in
the brain after administration of acetaminophen in vivo [12]
prompted us to study its effect following intracerebroventricular
injection in the mouse formalin test. These studies showed that
AM404 produces antinociception via activation of TRPV1
locally in the brain. Importantly, inhibition of TRPV1 by an
intracerebroventricular injection of capsazepine abolished the
antinociceptive effect of orally administered acetaminophen,
supporting the view that acetaminophen has a central site of
action [10,27]. TRPV1 is expressed in several brain areas of
importance for nociceptive signaling, including the periaque-
ductal gray [28–30]. Interestingly, there is extensive evidence in
the literature that the analgesic effect of acetaminophen in both
animals and man is dependent on bulbospinal serotonergic
pathways [8,31–35]. Injection of capsaicin into the ventrolateral
periaqueductal gray releases glutamate in the rostral ventrome-
dial medulla, which in turn activates inhibitory bulbospinal
pathways and produces antinociception [29,36]. Our finding that
acetaminophen acts via TRPV1 at the supraspinal level is
compatible with such a mechanism, although future studies are
needed to define the exact site(s) of action in the brain for this
TRPV1-mediated effect.
Besides the brain, the spinal cord and dorsal root ganglia also
express FAAH [12,37,38]. These tissues can catalyse the
biosynthesis of AM404 in vitro, as shown in tissue homogenates
incubated with p-aminophenol [12]. However, the in vitro
formation of AM404 was much smaller in the spinal cord and
dorsal root ganglia than in the brain under identical experimental
conditions [12]. Furthermore, only trace amounts of AM404 could
be detected in the rat spinal cord after administration of
acetaminophen in vivo [12]. Thus, although AM404 injected
intrathecally can produce antinociception in the mouse formalin
test [15], it seems unlikely that AM404 via activation of TRPV1 in
the spinal cord or dorsal root ganglia contributes to the
antinociceptive effect of acetaminophen.
Recent work has shown that some antinociceptive effects of
acetaminophen are lost in CB1
2/2 mice and inhibited by CB1
receptor antagonists in rats [6,39]. This is intriguing because,
acetaminophen does not interact with the endocannabinoid system
in vitro and fails to qualify as a cannabimimetic compound in the
classical tetrad test after oral administration in rats [6,40].
Furthermore, AM404 is a poor ligand at the CB1 receptor
[21,41]. In the present study, we found no effect of acetaminophen
on global levels of endocannabinoids in mouse and rat brain. It is
therefore unlikely that acetaminophen or any of its metabolites,
including AM404, produces antinociception via inhibition of
endocannabinoid uptake and degradation. In this context, it is
noteworthy that TRPV1-mediated nocifensive responses triggered
by capsaicin disappear in CB1
2/2 mice or in animals subjected to
pharmacological inhibition of the CB1 receptor [42,43]. This
indicates a functional interaction between TRPV1 and the CB1
Figure 3. Comparison of the effects of acetaminophen and
ibuprofen in various pain tests. (A) The antinociceptive effects of
oral administration of acetaminophen (AcAP; 200 mg/kg in mice and
300 mg/kg in rats) and intraperitoneal injection of ibuprofen (Ibu;
100 mg/kg) were assessed in (A,B) the formalin test, (C) the tail
immersion test and (D) the von Frey test. In the first phase of the
formalin test as well as the von Frey and the tail immersion tests,
acetaminophen produced an antinociceptive effect, whereas ibuprofen
was ineffective. Acetaminophen and ibuprofen inhibited the nocicep-
tive behavior during the second phase of the formalin test. In the tail
immersion and von Frey test tests, results are expressed as MPE (5):
[(post-treatment score – pre-treatment score)/(cut-off value – pre-
treatment score) 6100]. Basal pre-treatment threshold responses were
7.2960.43 s in the tail immersion test and 0.6760.08 g in the von Frey
test, respectively. All tests were performed 20 min after acetaminophen
or ibuprofen administration. Data are presented as mean 6 SEM (n=6–
8 per group). *P,0.05, **P,0.01 compared to vehicle.
doi:10.1371/journal.pone.0012748.g003
Brain TRPV1 and Acetaminophen
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12748Figure 4. The acetaminophen metabolite AM404 produces antinociception by activation of TRPV1 in the brain. (A)
Intracerebroventricular (i.c.v.) injection of AM404 (10 nmol) 5 min before injection of formalin into the mouse hind paw decreased biting and
licking during the first, but not the second phase of the formalin test (n=5–6). When AM404 (10 nmol) was administered 10 min after formalin, it also
decreased the second phase (15 to 30 min post-formalin) (n=10–12). (B) The role of TRPV1 in the action of AM404 was further investigated on the
first phase of the formalin test. The effect of AM404 (10 nmol) was inhibited by coinjection of AM404 with capsazepine (Cz; 100 nmol) and absent in
TRPV1
2/2 mice (n=5–8). (C) Injection of AM404 into the mouse hind paw induced a pronounced nocifencive behavior, as recorded during 5 min after
the injections (n=5–6). The nociceptive response to intraplantar injection AM404 (60 nmol) was absent in TRPV1
2/2 mice (n=6). Data are presented
as mean 6 SEM. *P,0.05, ***P,0.001 compared to vehicle in wild-type mice.
doi:10.1371/journal.pone.0012748.g004
Brain TRPV1 and Acetaminophen
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acetaminophen were suppressed following genetic or pharmaco-
logical inactivation of the CB1 receptor [6,39]. Clearly, more
studies are needed to understand the complex interplay between
TRPV1 and the CB1 receptor in the nervous system.
As early as 1972, Flower and Vane proposed that acetamino-
phen exerts its therapeutic effects by inhibiting prostaglandin
formation in the central nervous system [44]. We found that
acetaminophen at an oral dose of 200 mg/kg, which produced
robust antinociceptive effects, had no effect on the content of
PGE2 in brain. However, when administered at an intraperitoneal
dose of 300 mg/kg, it was almost as effective as ibuprofen to
reduce PGE2 contents in the brain. This dose of acetaminophen
also reduced the levels of prostanoids in peripheral tissues, which
does not support the view that acetaminophen inhibits COX
selectively in the brain. Our studies on TRPV1
2/2 mice also
revealed a TRPV1-independent effect of this dose of acetamino-
phen in the formalin test. Thus, multiple dose-dependent effects
may explain why there is no consensus regarding the mechanism
of action of acetaminophen.
The expression pattern in adult animals and the close
evolutionary development of TRPV1 and FAAH implicate a
functional relationship between these proteins in the central
nervous system [28,37,45,46]. This together with our finding that
acetaminophen via its metabolite p-aminophenol is conjugated to
AM404 in the brain [12] indicate that AM404 may be formed in
TRPV1-containing neurons or adjacent cells in the central nervous
system following administration of acetaminophen (Fig. 6). The
involvement of both FAAH and TRPV1 in the pharmacological
action of acetaminophen and the coexpression of these proteins in
the brain provide a strategy for targeted delivery of TRPV1
activators to the nociceptive system. This may circumvent some of
the feared pulmonary and cardiovascular adverse effects of
systemically administered TRPV1 activators [47,48]. Understand-
ing the substrate specificity and the kinetics of fatty acid
conjugation may help to develop novel analgesics that are more
effective and less toxic than acetaminophen. Our study also raises
the possibility that other high dose analgesic and/or anti-
inflammatory agents may undergo a similar FAAH-mediated
bioactivation, contributing to their pharmacological effects.
In conclusion, we provide evidence that TRPV1 in brain
mediates the antinociceptive effect of acetaminophen and propose
a strategy for developing TRPV1 active oral analgesics based on
the coexpression of TRPV1 and FAAH in the central nervous
system.
Materials and Methods
Ethics statement
All animal procedures were approved by the Regional ethics
committee for animal experiments for the region Auvergne in
France (CEMEA Auvergne; nr CE 0908 and CE 1010) and
Malmo ¨/Lund animal ethics committee (nr: M 26-07).
Animals and administration of drugs
Adult C57BL/6 mice (20–30 g) of either sex were purchased
from Taconic (Denmark) or Charles River Laboratories (France).
Sprague-Dawley rats (175–250 g) were obtained from Charles
River Laboratories (France and Germany). Only male animals
were used in the nociceptive tests. TRPV1 and FAAH knockout
mice were originally generated by David Julius [24] and Benjamin
Cravatt [49]. Animals were housed under standard conditions
(21–22uC; 12/12 h light/dark cycle) with food and water ad
libitum. Acetaminophen (100, 200 or 300 mg/kg) and ibuprofen
(100 mg/kg) were administered by oral or intraperitoneal
injections in volumes of 10 ml/kg. The TRPV1 antagonist
capsazepine (10 mg/kg) was administered intraperitoneally in a
volume of 1 ml/kg. Drugs for intracerebroventricular (left lateral
ventricle) and intraplantar (hindpaw) administration to mice were
injected in volumes of 1 and 25 ml, respectively. In the biochemical
studies, the animals were anesthetized by CO2 or isoflurane
Figure 6. Mechanism behind the TRPV1-mediated antinocicep-
tive effect of acetaminophen. Acetaminophen is metabolized to p-
aminophenol (p-AP) mainly in the liver. p-Aminophenol is subsequently
conjugated with arachidonic acid (AA) in FAAH-containing cells in the
nervous system, including neurons expressing TRPV1, leading to the
formation of the TRPV1 activator AM404. As suggested for capsaicin,
AM404 may activate TRPV1 from inside of the cell [53,54]. In contrast to
AM404, acetaminophen and p-aminophenol do not directly interact
with TRPV1 [12]. Activation of TRPV1 could produce antinociception by
stimulation of bulbospinal descending inhibitory pathways in the
periaqueductal gray [28].
doi:10.1371/journal.pone.0012748.g006
Figure 5. The antinociceptive effect of acetaminophen is dependent on TRPV1 in brain. The effect of acetaminophen (AcAP; 200 mg/kg
p.o.) was assessed in (A) the formalin test, (B) the tail immersion test and (C) the von Frey test. In TRPV1
2/2 mice, acetaminophen failed to produce
antinociception, while it was effective in TRPV1
+/+ mice in the same tests. All tests were performed 20 min after acetaminophen administration. In the
tail immersion and von Frey test tests, results are expressed as MPE (%): [(post-treatment score – pre-treatment score)/(cut-off value – pre-treatment
score)6100]. Basal pre-treatment threshold responses were 7.5960.79 and 8.6360.88 s in the tail immersion test and 0.6760.08 and 0.6860.10 g in
the von Frey test for TRPV1
+/+ and TRPV1
2/2 mice, respectively. (D) The effect of acetaminophen (300 mg/kg p.o.) in the formalin test was also
examined in rats pre-treated with capsazepine (Cz; 10 mg/kg i.p.) or vehicle 45 min before injection of formalin. Pre-treatment with capsazepine
suppressed the antinociceptive effect of acetaminophen. (E) The antinociceptive effect of acetaminophen (AcAP; 200 mg/kg) on both phases of the
formalin test was inhibited by intracerebroventricular injection of capsazepine (100 nmol) 5 min before oral administration of acetaminophen. Data
are presented as mean 6 SEM (n=5–8 per group). *P,0.05, **P,0.01, ***P,0.001 compared to vehicle.
doi:10.1371/journal.pone.0012748.g005
Brain TRPV1 and Acetaminophen
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12748inhalation and decapitated 20 min after injection of acetamino-
phen or ibuprofen. Thereafter the brain, kidneys and blood were
collected, snap frozen in liquid nitrogen and kept on dry ice until
stored at 270uC. Blood was collected in test tubes containing
60 ml buffered citrate.
In vivo tests
For assessment of locomotor activity, mice were placed in
actimetry boxes (Actisystem, Apelex, Passy, France) and sponta-
neous motor activity was assessed by determining the number of
crossings of light beams during 15 min. The test was performed
20 min after acetaminophen or vehicle (NaCl 0.9%) administra-
tion. In the formalin test, mice and rats were first acclimatized for
20 min in the test chamber. For assessment of antinociceptive
effects of acetaminophen or ibuprofen in the formalin test, drugs
or vehicle were administered systemically 20 min and 40 min
prior to an intraplantar injection of a 2.5% formalin solution
(25 ml and 50 ml) into a hindpaw in mice and rats, respectively. In
the rat formalin test, acetaminophen-induced antinociception was
also assessed in animals given capsazepine or its vehicle
intraperitoneally 5 min prior to acetaminophen. Spontaneous
biting and licking of the injected paw were monitored 0–5 min
(phase 1) and 15–40 min (phase 2) in mice and 0–5 min (phase 1)
and 20–40 min (phase 2) in rats after formalin injection to assess
effects on both phases of the nociceptive response. In the tail
immersion test, tails of mice were submerged in a water bath at
46uC until withdrawal was observed (cut-off 15 s). Four baseline
latencies were measured and averaged before drug administration.
Withdrawal latencies were measured 20 min after drug or vehicle
administration. Calibrated von Frey filaments (0.0045–5.4950 g)
was used to achieve light noxious mechanical stimulation in mice
[50]. Tests were commenced after one hour of habituation. The
filaments, tested in order of increasing stiffness, were applied five
times perpendicular to the plantar surface of the hindpaw and
pressed until bending. The first filament that evoked at least three
consecutive responses was assigned as the threshold (cut-off 2 g).
Drugs or vehicle was given 20 min before the start of the test. In
the tail immersion and the von Frey tests, maximal possible effect
(MPE) was calculated to facilitate inter-group comparisons, using a
pre-determined cut-off value as follows: [(post-treatment score –
pre-treatment score)/(cut-off value – pre-treatment score)]. To
address whether the antinociceptive effect of acetaminophen was
centrally mediated, the effect of intracerebroventricular injection
of AM404 in the formalin test was investigated by injecting this
compound either 5 min before or 10 min after the injection of
formalin in mice. Spontaneous biting and licking of the paw was
then monitored 0–5 min (phase 1) and 15–30 min (phase 2) after
the formalin injection. Intracerebroventricular injections of
capsazepine were also performed in mice either simultaneously
with or 5 min before the administrations of AM404 (i.c.v.) and
acetaminophen (p.o.), respectively. Finally, after intraplantar
injection of AM404, the biting and licking behavior was recorded
for 5 min. All behavioral experiments were performed in a quiet
room and evaluated by a single investigator in a blinded manner.
Each animal was exposed to only one treatment. Treatments were
randomized in blocks and the experiments in each block were
performed within the same time interval to avoid environmental
influences.
Quantification of prostanoids and endocannabinoids
Mouse brain and kidneys were homogenized in 1 ml Tris buffer
(10 mM; pH 7.6), containing ethylenediaminetetraacetic acid
(EDTA; 1 mM), ascorbic acid (0.3 mM), methylarachidonylfluor-
ophosphonate (MAFP; 10 mM) and indomethacin (10 mM).
Aliquots (200 ml) of blood and homogenates were precipitated
with one ml ice-cold acetone, containing 0.1 mM[
2H8]-labeled
anandamide and 0.1 mM[
2H4]-labeled PGE2 as internal stan-
dards. After centrifugation at 25200 g for 30 min (4uC), the
supernatants were collected in polypropylene tubes and vacuum
evaporated [12]. The extraction residues were reconstituted in
100 ml methanol and sample aliquots of 5 ml were injected into a
Perkin Elmer 200 liquid chromatography system with an
autosampler (Applied Biosystems, Norfolk, CT) coupled to an
API 3000 tandem mass spectrometer (LC-MS-MS; Applied
Biosystems/MDS-SCIEX, Toronto, Canada) [12]. A Genesis C8
column (2062.1 mm; Jones, Lakewood, CO) was used for all
analyses. For analysis of prostanoids, a gradient in the mobile
phase was applied in 6 min starting at 25% and ending at 100%
methanol. The column was then kept at 100% methanol for three
min. The column was reconditioned in 25% methanol for two
min. The electrospray interface was operating in the positive ion
mode at 370uC and the ion spray voltage was 24000 volts. M/z
351.3/271.0 with a collision energy (CE) of 226 volts and a
declustering potential (DP) of 235 volts was used for determina-
tion of PGE2. M/z 355.3/275.3 (CE 226 volts, DP 238 volts) and
m/z 369.2/195.0 (CE 217 volts, DP 227 volts) were used for
determination of [
2H4]-labeled PGE2 and thromboxane B2,
respectively. For analysis of endocannabinoids, a gradient in the
mobile phase was applied in 6 min starting at 75% and ending at
100% methanol. The column was then reconditioned in 75%
methanol for two min. The electrospray interface was operating in
the positive ion mode at 370uC, and the ion spray voltage and DP
were set to 5000 volts and 40 volts, respectively. M/z 348.2/62.0
(CE 35 volts), 356.4/63.0 (CE 35 volts), m/z 300.5/62 (CE 35
volts) and m/z 379.2/287.0 (CE 15 volts) were used for the
determinations of anandamide, [
2H8]-labeled anandamide, N-
palmitoylethanolamide and 2-arachidonoylglycerol, respectively.
The contents of these lipids were expressed either in mol or as
normalized peak areas (nPA) and related to the protein content in
the samples. The nPA was obtained by dividing the peak area for
the analytes with the peak area for the internal standard in the
same sample. Since 2-arachidonoylglycerol is non-enzymatically
converted to 1-arachidonoylglycerol, the content of 2-arachido-
noylglycerol was estimated as the sum of these lipids [51,52]. The
detection limits were calculated as the concentration correspond-
ing to three times the standard deviation of the blanks. When
levels were below detection limit, numerical values of half the
detection limit were used in the calculations.
Calculations and statistics
Data are presented as means 6 standard error of the mean, and
n indicates the number of animals used. The percent reduction of
prostanoid contents was calculated from the logarithm trans-
formed values. GraphPad Prism 5 software (GraphPad Software,
San Diego, CA) was used for drawing graphs. Mann-Whitney U-
test and Wilcoxon signed rank test were used for statistical analysis
of paired and unpaired data. Statistical significance was accepted
when P,0.05.
Drugs
Acetaminophen, ibuprofen (Sigma-Aldrich, Lyon or Stockholm,
France or Sweden) and indomethacin (ConfortidH, Dumex,
Copenhagen, Denmark) were dissolved in and diluted with saline
or water. Capsazepine (Sigma-Aldrich) was dissolved in 10%
dimethyl sulfoxide (DMSO) in saline for systemic administration
or in 10% DMSO/2.5% Tween 80 in saline for intracerebroven-
tricular administration. AM404 (Tocris Bioscience, Bristol, UK)
was dissolved in 10% DMSO/2.5% Tween 80 in saline.
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and MAFP (Cayman Chemical, Ann Arbor, M.I.) were all
dissolved in and diluted with ethanol.
Supporting Information
Figure S1 Effect of acetaminophen on endocannabinoid
contents in rat brain. The contents of anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) did not differ between animals
exposed to acetaminophen (300 mg/kg p.o.) or vehicle for
15 min. Y-axis shows values as normalized peak area (nPA),
obtained by dividing the peak area for the analytes with the peak
area for the internal standard (0.1 mM d8-anandamide) in the
sample. Data are given as mean 6 SEM (n=6).
Found at: doi:10.1371/journal.pone.0012748.s001 (2.09 MB
TIF)
Figure S2 A high intraperitoneal dose of acetaminophen
reduces prostanoid contents and evokes TRPV1-independent
antinociceptive effects in mice. (A) Acetaminophen (300 mg/kg
i.p.) and ibuprofen (Ibu; 100 mg/kg i.p.) significantly reduced the
content of prostaglandin E2 (PGE2) or thromboxane B2 (TXB2)
in brain, kidney and blood. Tissues were collected 20 min after
injection of drug or vehicle. The reduction is presented as a
percentage of the vehicle for each group. Data are given as mean
6 SEM (n=6). **P,0.01 compared to vehicle treated animals.
(B) The effect of acetaminophen (300 mg/kg i.p.; AcAP) in the
formalin test was intact in TRPV1
2/2 mice. Acetaminophen was
administered 20 min before intraplantar injection of formalin.
Data are given as mean 6 SEM (n=6). **P,0.01 compared to
vehicle.
Found at: doi:10.1371/journal.pone.0012748.s002 (4.32 MB
TIF)
Table S1 Contents of endocannabinoids (pmol/mg protein) in
the mouse brain 20 min after injection (i.p.) of vehicle or
acetaminophen at a dose of 300 mg/kg. Data are given as mean
6 SEM (n=6).
Found at: doi:10.1371/journal.pone.0012748.s003 (0.03 MB
DOC)
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